ClinicalTrials.gg
CompletedNCT01872598Updated Sep 29, 2023

Masitinib in Patients With Mild to Moderate Alzheimer's Disease

A Phase 3 interventional study of Masitinib and Placebo in Alzheimer Disease, sponsored by AB Science. Completed at 6 sites in 6 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-09-29.

Sponsored by AB Science · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Jan 2012, registered Jun 2013).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
721
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Alzheimer Disease with a site in Bulgaria — 8 open to participants now, 8 under way, 5 of them phase 3. Alzheimer Disease · Bulgaria.

Enrollment
15th of 38
721 · median 589
Started
2012
with 1 other
Phase 3
26 of 39
5 open now
Registered
15th of 39
by date
Lead sponsor
1 of 39
AB Science

Among the 39 studies in Alzheimer Disease with a site in Bulgaria, this one is the 15th largest by enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2012, is one of 26 in phase 3, and was the 15th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

8 of the 39 studies in Alzheimer Disease with a site in Bulgaria are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Alzheimer Disease with a site in Bulgaria, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of masitinib for the treatment of mild to moderate Alzheimer's Disease. Masitinib will be administered as add-on therapy in patients who have been treated for a minimum of 6 months with a stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine.

Read the detailed description

Actual standard treatment for mild to moderately severe Alzheimer's dementia includes acetylcholinesterase inhibitors (donepezil, rivastigmine and galantamine) and a NMDA receptor antagonist (memantine for moderate to severe Alzheimer's disease). These medications have shown to have an effect on some cognitive and non cognitive symptoms of the pathology. However, their efficacy remains limited and may decrease with time. There is an unmet medical need in this pathology. Masitinib is a selective tyrosine kinase inhibitor that is thought to exert a neuroprotective effect through its activity on mast cells and other non-neuronal cells of the central nervous system, with subsequent modulation of inflammatory and neurodegenerative processes, as well as possibly disruption of the Aβ signaling cascade via inhibition of the Fyn signaling pathway. This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study of oral masitinib. The objective of this study is to compare the efficacy and safety of masitinib at various doses versus matched placebo in the treatment of patients with mild to moderate Alzheimer's Disease. Masitinib will be administered as add-on therapy in patients who have been treated for a minimum of 6 months with a stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine. Approximately 675 patients will be randomized into 5 treatment groups. The co-primary outcome measures are the Alzheimer's Disease Cooperative Study Activities of Daily Living score (ADCS-ADL), and Alzheimer's Disease Assessment Scale-Cognitive Subscale score (ADAS-Cog) after 24 weeks of treatment.

03

Conditions studied

  • Alzheimer Disease

Keywords

  • Alzheimer
  • dementia
  • cognitive disease
  • memory loss
  • cerebrovascular disease
  • tyrosine kinase inhibitor
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient with dementia of Alzheimer's type, according to the criteria (DSM-IV)
  2. Patient with probable Alzheimer' disease according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria (NINCDS-ADRDA)
  3. Patient with ≥ 12 and ≤ 25 at baseline
  4. Patient treated for a minimum of 6 months with a stable dose of cholinesterase inhibitors (donepezil, rivastigmine or galantamine) at baseline, and/or a stable dose of memantine for a minimum of 6 months at baseline, with no changes foreseen in therapy throughout the study.

Exclusion criteria

Exclusion criteria include:

  1. Patient with any other cause of dementia not due to Alzheimer's disease.
  2. Patient with Alzheimer disease with severe forms of delusions or delirium (patients with light and mild forms of delusions and delirium will be allowed in the study).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
721 participants (actual)

Study arms

  • Experimental
    Masitinib escalating dose

    Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment

    Drug: Masitinib · Drug: Standard of care

  • Experimental
    Masitinib fixed dose (4.5 mg/kg/day)

    Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily.

    Drug: Masitinib · Drug: Standard of care

  • Experimental
    Masitinib fixed dose (3.0 mg/kg/day)

    Participants receive masitinib at 3.0 mg/kg/day, given orally twice daily.

    Drug: Masitinib · Drug: Standard of care

  • Placebo comparator
    Placebo (escalating dose)

    Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment

    Drug: Placebo · Drug: Standard of care

  • Placebo comparator
    Placebo (fixed dose)

    Participants receive fixed dose placebo, given orally twice daily

    Drug: Placebo · Drug: Standard of care

Interventions

  • Also known as: AB1010

  • DrugPlacebo

    Also known as: Placebo Oral Tablet

  • DrugStandard of care

    stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.

06

What researchers measure

Primary outcomes

  1. ADCS-ADL

    Change in the Alzheimer's Disease Cooperative Study Activities of Daily Living score (ADCS-ADL).

    Time frame: 24 weeks

  2. ADAS-Cog

    Change in the Alzheimer's Disease Assessment Scale-Cognitive Subscale score (ADAS-Cog).

    Time frame: 24 weeks

Secondary outcomes

  1. MMSE

    Change in Mini Mental State Examination (MMSE)

    Time frame: 24 weeks

  2. CIBIC-plus

    Clinician's Interview Based Impression of Change-plus (CIBIC-plus)

    Time frame: 24 weeks

07

Study locations

6 sites
  • MHAT Sveta Marina
    Varna, 9010, Bulgaria
  • General Hospital of Thessaloniki
    Thessaloniki, 570 10, Greece
  • Centrum Zdrowia Stołeczna 7
    Białystok, 15-879, Poland
  • Spitalul Universitar de Urgenta Elias
    Bucuresti, 013686, Romania
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Municipal Institution Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnikov
    Dnipropetrovsk, 49005, Ukraine
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in Dec 2020, 107 months.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 107 months is above that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2013
First posted
Jun 7, 2013
StartActual
Jan 2012
Primary completionActual
Dec 2020
CompletionActual
Dec 2020
Results delay requested
Dec 7, 2020
Last update
Sep 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01872598
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Jun 7, 2013
Start date
Jan 2012
Primary completion
Dec 2020
Completion
Dec 2020
Last update
Sep 29, 2023

Study contacts

Bruno DUBOIS, M.D., Ph.D.
principal investigator · Pitié-Salpétrière

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion